secwatch.observer — SEC 8-K summary
======================================

Issuer:     ONCOLYTICS BIOTECH INC (ONCY)
CIK:        0001129928
Form:       8-K
Filed at:   2026-07-08T20:23:21+00:00
Accession:  0001104659-26-081797
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncolytics Biotech disengages EY, engages Baker Tilly as auditor after restructuring
--------------------------------------------------------------------------------

- Audit committee voted to disengage EY and engage Baker Tilly for fiscal 2026, subject to client acceptance.
- EY's reports for 2024 and 2025 contained no adverse opinion but included a going-concern explanatory paragraph.
- No disagreements or reportable events with EY during the fiscal years ended 2024 and 2025.
- Company provided EY with a copy of the 8-K and requested a letter to the SEC regarding the statements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1129928/000110465926081797/0001104659-26-081797-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1129928/000110465926081797/tm2620055d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-081797

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer